PureVax Feline 3 (Canada)

Company: Merial

Feline Rhinotracheitis-Calici-Panleukopenia Vaccine

Modified Live Virus

RCP-SWD

Description

PUREVAX^® Feline 3 contains a lyophilized suspension of modified live feline rhinotracheitis, calici, and panleukopenia viruses, each propagated in a stable cell line, plus sterile water diluent. Safety and immunogenicity of this product have been demonstrated by vaccination and challenge tests in susceptible cats.

PureVax Feline 3 Indications

PUREVAX^® Feline 3 is recommended for the vaccination of healthy cats 6 weeks of age or older for prevention of disease due to feline rhinotracheitis, calici, and panleukopenia viruses.

DOSAGE: Reconstitute the lyophilized vaccine with accompanying liquid diluent and aseptically inject 1 mL (1 dose) subcutaneously or intramuscularly into healthy cats. For primary vaccination, revaccinate with a second 1 mL dose 3 to 4 weeks later. Cats younger than 12 weeks of age should be revaccinated with a single 1 mL dose every 3 to 4 weeks, the last dose given at or over 12 weeks of age. Revaccinate annually with a single 1 mL dose.

Precautions

Store at 2-7°C (35-45°F). Use immediately after reconstitution. Do not use chemicals to sterilize syringes and needles. Burn the container and all unused contents. Contains gentamicin as a preservative. Do not vaccinate pregnant cats. In rare instances, administration of vaccines may cause lethargy, fever, and inflammatory or hypersensitivity types of reactions. Treatment may include antihistamines, anti-inflammatories, and/or epinephrine.

SOLD TO VETERINARIANS ONLY.

For Veterinary Use Only.

PUREVAX is a registered trademark of MERIAL.

Manufactured By MERIAL INC., Athens, GA 30601 USA

U.S. Vet. Lic. No. 298

1-888-Merial-1 (1-888-637-4251)

Distributed In Canada By MERIAL CANADA, INC., Baie d’Urfé, (Québec), H9X 4B6, Canada

CPN: 11820462